@article{7f90a6cb290b43c086b909d43cf8198d,
title = "Laterality and region-specific tau phosphorylation correlate with PTSD-related behavioral traits in rats exposed to repetitive low-level blast",
abstract = "Military veterans who experience blast-related traumatic brain injuries often suffer from chronic cognitive and neurobehavioral syndromes. Reports of abnormal tau processing following blast injury have raised concerns that some cases may have a neurodegenerative basis. Rats exposed to repetitive low-level blast exhibit chronic neurobehavioral traits and accumulate tau phosphorylated at threonine 181 (Thr181). Using data previously reported in separate studies we tested the hypothesis that region-specific patterns of Thr181 phosphorylation correlate with behavioral measures also previously determined and reported in the same animals. Elevated p-tau Thr181 in anterior neocortical regions and right hippocampus correlated with anxiety as well as fear learning and novel object localization. There were no correlations with levels in amygdala or posterior neocortical regions. Particularly striking were asymmetrical effects on the right and left hippocampus. No systematic variation in head orientation toward the blast wave seems to explain the laterality. Levels did not correlate with behavioral measures of hyperarousal. Results were specific to Thr181 in that no correlations were observed for three other phospho-acceptor sites (threonine 231, serine 396, and serine 404). No consistent correlations were linked with total tau. These correlations are significant in suggesting that p-tau accumulation in anterior neocortical regions and the hippocampus may lead to disinhibited amygdala function without p-tau elevation in the amygdala itself. They also suggest an association linking blast injury with tauopathy, which has implications for understanding the relationship of chronic blast-related neurobehavioral syndromes in humans to neurodegenerative diseases.",
keywords = "Animal model, Behavior, Blast, Laterality, Rat, Tau, Traumatic brain injury",
author = "{Perez Garcia}, Georgina and {De Gasperi}, Rita and {Gama Sosa}, {Miguel A.} and Perez, {Gissel M.} and Alena Otero-Pagan and Dylan Pryor and Rania Abutarboush and Usmah Kawoos and Hof, {Patrick R.} and Dickstein, {Dara L.} and Cook, {David G.} and Sam Gandy and Ahlers, {Stephen T.} and Elder, {Gregory A.}",
note = "Funding Information: This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000996 (GE), 1I01RX002660 (GE), 1I21RX003019 (GE), 1I01RX000684 (SG), and 1I01RX002333 (SG), the Department of Veterans Affairs Office of Research and Development Medical Research Service 1I01BX004067 (GE) and 1I01BX002311 (DC), Department of Defense work unit number 0000B999.0000.000.A1503 (STA), the Alzheimer{\textquoteright}s Drug Discovery Foundation (SG) and by P50AG005138 and P30AG066514 to Mary Sano (SG, PRH). All studies involving animals were reviewed and approved by the Institutional Animal Care and Use Committees of the Walter Reed Army Institute of Research (WRAIR)/Naval Medical Research Center and the James J. Peters VA Medical Center. Studies were conducted in compliance with the Public Health Service policy on the humane care and use of laboratory animals, the NIH Guide for the Care and Use of Laboratory Animals, and all applicable Federal regulations governing the protection of animals in research. The views expressed in this article reflect the results of research conducted by the authors and do not necessarily reflect the official policy or position of the Uniformed Services University of the Health Sciences (USUHS), The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of the Navy, or the Department of Defense (DoD). Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government. Some of the authors are military service members or federal/contracted employees of the United States Government. This work was prepared as part of my official duties. Title 17 U.S.C. § 105 provides that {\textquoteleft}Copyright protection under this title is not available for any work of the United States Government.{\textquoteright} Title 17 U.S.C. § 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person{\textquoteright}s official duties. Funding Information: This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000996 (GE), 1I01RX002660 (GE), 1I21RX003019 (GE), 1I01RX000684 (SG), and 1I01RX002333 (SG), the Department of Veterans Affairs Office of Research and Development Medical Research Service 1I01BX004067 (GE) and 1I01BX002311 (DC), Department of Defense work unit number 0000B999.0000.000.A1503 (STA), the Alzheimer{\textquoteright}s Drug Discovery Foundation (SG) and by P50AG005138 and P30AG066514 to Mary Sano (SG, PRH). The funding agencies played no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
month = dec,
doi = "10.1186/s40478-021-01128-3",
language = "English",
volume = "9",
journal = "Acta neuropathologica communications",
issn = "2051-5960",
publisher = "BioMed Central Ltd.",
number = "1",
}